- Home
- LGI vs CRDF Comparison
LGI vs CRDF Comparison
Compare LGI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGI
- CRDF
- Stock Information
- Founded
- LGI 2004
- CRDF 1999
- Country
- LGI United States
- CRDF United States
- Employees
- LGI N/A
- CRDF N/A
- Industry
- LGI
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LGI
- CRDF Health Care
- Exchange
- LGI Nasdaq
- CRDF Nasdaq
- Market Cap
- LGI 210.5M
- CRDF 233.5M
- IPO Year
- LGI N/A
- CRDF N/A
- Fundamental
- Price
- LGI $17.05
- CRDF $3.97
- Analyst Decision
- LGI
- CRDF Strong Buy
- Analyst Count
- LGI 0
- CRDF 6
- Target Price
- LGI N/A
- CRDF $11.92
- AVG Volume (30 Days)
- LGI 41.1K
- CRDF 1.6M
- Earning Date
- LGI 01-01-0001
- CRDF 08-07-2025
- Dividend Yield
- LGI 7.10%
- CRDF N/A
- EPS Growth
- LGI N/A
- CRDF N/A
- EPS
- LGI N/A
- CRDF N/A
- Revenue
- LGI N/A
- CRDF $587,000.00
- Revenue This Year
- LGI N/A
- CRDF N/A
- Revenue Next Year
- LGI N/A
- CRDF N/A
- P/E Ratio
- LGI N/A
- CRDF N/A
- Revenue Growth
- LGI N/A
- CRDF N/A
- 52 Week Low
- LGI $12.66
- CRDF $2.01
- 52 Week High
- LGI $16.68
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- LGI 67.44
- CRDF 52.55
- Support Level
- LGI $16.50
- CRDF $3.73
- Resistance Level
- LGI $16.77
- CRDF $4.52
- Average True Range (ATR)
- LGI 0.18
- CRDF 0.30
- MACD
- LGI -0.01
- CRDF -0.02
- Stochastic Oscillator
- LGI 92.33
- CRDF 30.59
About LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.